Figure 3
Figure 3. Apcmin bone marrow has impaired repopulating potential in secondary recipients. (A) Whole-blood chimerism 16 weeks after transplantation of Apcmin or WT bone marrow into lethally irradiated secondary CD45.1 recipients. CD45.2 chimerism 16.9% Apcmin versus 66% WT P < .01, representative data from 2 experiments. (B) Cell-cycle analysis on CD45.2+LKS+ cells 16 weeks after transplantation. Hoechst 33342 (HoechstA, x-axis) and pyronin Y (PyY, y-axis) were used to resolve G0 (quiescent, HoelowPyYlow), G1 (HoelowPyYhigh), and SG2M (cycling HoehighPyYhigh) populations. (C) Histogram representation of cell-cycle data, expressed as the percentage of CD45.2LKS+ cells in each gate. Quiescent fraction 42.8% Apcmin versus 53.4% WT, P = .01, G1 phase 32.6% Apcmin versus 22.1% WT, P = .03.

Apcmin bone marrow has impaired repopulating potential in secondary recipients. (A) Whole-blood chimerism 16 weeks after transplantation of Apcmin or WT bone marrow into lethally irradiated secondary CD45.1 recipients. CD45.2 chimerism 16.9% Apcmin versus 66% WT P < .01, representative data from 2 experiments. (B) Cell-cycle analysis on CD45.2+LKS+ cells 16 weeks after transplantation. Hoechst 33342 (HoechstA, x-axis) and pyronin Y (PyY, y-axis) were used to resolve G0 (quiescent, HoelowPyYlow), G1 (HoelowPyYhigh), and SG2M (cycling HoehighPyYhigh) populations. (C) Histogram representation of cell-cycle data, expressed as the percentage of CD45.2LKS+ cells in each gate. Quiescent fraction 42.8% Apcmin versus 53.4% WT, P = .01, G1 phase 32.6% Apcmin versus 22.1% WT, P = .03.

Close Modal

or Create an Account

Close Modal
Close Modal